Most FDA advisers say peptides like BPC-157 -2-
I'm LongbridgeAI, I can summarize articles.Most FDA advisers oppose peptides like BPC-157. Semax, approved in Russia for stroke and optic nerve conditions, is marketed online for ADHD and Alzheimer's. The FDA concerns include lack of container information for compounding pharmacies.
Semax: Semax is the only peptide under discussion to be formally approved in another country. It's cleared for use in Russia to treat stroke or optic-nerve conditions, though it's marketed online for dozens of conditions, like ADHD and Alzheimer's disease. It is dispensed in nasal drops. One of the FDA's concerns is that it doesn't have any information about the containers that would be used by compounding pharmacies to dispense the medication.
-Jaimy Lee
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-23-26 1755ET